Evidence map›Paper›PMID 38976182›Full record

ArticleInternational journal of clinical oncology2024

Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement.

Tokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, Dai Takamatsu, Yoshiyuki Matsui, Akira Yokomizo, Ryoichi Saito, Shuichi Morizane, Makito Miyake, Masakazu Tsutsumi and 26 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Tokiyoshi TanegashimaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-3306-4858
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Dai TakamatsuDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yoshiyuki MatsuiDepartment of Urology, National Cancer Center Hospital, Tokyo, Japan.
Akira YokomizoDepartment of Urology, Harasanshin Hospital, Fukuoka, Japan.
Ryoichi SaitoDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Shuichi MorizaneDivision of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Makito MiyakeDepartment of Urology, Nara Medical University, Kashihara, Japan.
Masakazu TsutsumiDepartment of Urology, Hitachi General Hospital, Hitachi, Japan.
Yoshiyuki YamamotoDepartment of Urology, Osaka International Cancer Institute, Osaka, Japan.
Kojiro TashiroDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Ryotaro TomidaDepartment of Urology, Shikoku Cancer Center, Matsuyama, Japan.
Kohei EdamuraDepartment of Urology, Okayama University, Okayama, Japan.
Shintaro NaritaDepartment of Urology, Akita University, Akita, Japan.
Takahiro YamaguchiDepartment of Urology, Kumamoto University, Kumamoto, Japan.
Takashi KasaharaDivision of Urology, Department of Regenerative and Transplant Medicine, Niigata University, Niigata, Japan.
Kohei HashimotoDepartment of Urology, Sapporo Medical University, Sapporo, Japan.
Masashi KatoDepartment of Urology, Nagoya University, Nagoya, Japan.
Takayuki YoshinoDepartment of Urology, University of Tsukuba, Tsukuba, Japan.
Shusuke AkamatsuDepartment of Urology, Kyoto University, Kyoto, Japan.
Akihiro MatsukawaDepartment of Urology, Kashiwa Hospital, The Jikei University, Chiba, Japan.
Tomoyuki KanekoDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Ryuji MatsumotoDepartment of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan.
Akira JorakuDepartment of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan.
Manabu KatoDepartment of Nephro-Urologic Surgery and Andrology, Mie University, Tsu, Japan.
Toshihiro SaitoDepartment of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
Takuma KatoDepartment of Urology, Kagawa University, Kagawa, Japan.
Shuichi TataranoDepartment of Urology, Kagoshima University, Kagoshima, Japan.
Shinichi SakamotoDepartment of Urology, Chiba University, Chiba, Japan.
Hidenori KannoDepartment of Urology, Yamagata University, Yamagata, Japan.
Naoki TeradaDepartment of Urology, Miyazaki University, Miyazaki, Japan.
Naotaka NishiyamaDepartment of Urology, University of Toyama, Toyama, Japan.
Hiroshi KitamuraDepartment of Urology, University of Toyama, Toyama, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Japanese Urological Oncology Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe therapeutic role of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) for prostate cancer is not established. In clinical practice, PLND is primarily performed in cases of high-risk prostate cancer. The detection of lymph node metastasis plays a crucial role in determining the need for subsequent treatments. This study aims to evaluate the prognosis of prostate cancer patients with lymph node involvement (LNI) by stratifying them based on postoperative prostate-specific antigen (PSA) levels to identify biomarkers that can guide postoperative treatment strategies.

methodsAnalysis was conducted on 383 patients, selected from 572 initially eligible, who underwent RP with LNI across 33 Japanese Urological Oncology Group institutions from 2006 to 2019. Patients were grouped according to postoperative PSA levels and salvage treatments received. Follow-up focused on castration resistance-free survival (CRFS), metastasis-free survival (MFS), and overall survival (OS).

resultsIn the persistent PSA group (PSA ≥ 0.1 ng/mL), CRFS and MFS were significantly shorter compared to the non-persistent PSA group (PSA < 0.1 ng/mL), and there was a tendency for shorter OS. In the persistent PSA group, patients with postoperative PSA values above the median (PSA ≥ 0.52 ng/mL) showed shorter CRFS and MFS. Furthermore, in the PSA ≥ 0.52 group, androgen deprivation therapy (ADT) plus radiotherapy (RT) combination had prolonged CRFS and MFS compared with ADT alone.

conclusionsThis study provides valuable insights into stratifying patients based on postoperative PSA levels to tailor postoperative treatment strategies, potentially improving the prognosis of prostate cancer patients with LNI.

Indexed as

Lymphatic MetastasisLymph Node ExcisionProstatectomyProstate-Specific AntigenProstatic NeoplasmsAgedAndrogen AntagonistsHumansLymph NodesMaleMiddle AgedPostoperative PeriodPrognosisRetrospective StudiesSalvage TherapyAndrogen AntagonistsProstate-Specific AntigenAndrogen deprivation therapyLymph node involvementPersistent PSARadical prostatectomyRadiotherapy

Identifiers

PMID38976182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.